[ad_1]
Both companies said the vaccine boosted an immune response in the 5-11 age group in the second and third stages of their experience, equivalent to the immunity achieved in the 16-25 age group.
“In terms of safety, the results were also generally equivalent for the older group,” they added.
“Since July, pediatric cases of COVID-19 have increased by almost 240% in the United States, highlighting the public health need for vaccination,” said Albert Burla, CEO of Pfizer, in a Press release.
“These trial results provide a solid basis for seeking approval of our vaccine for children aged 5 to 11 years old, and we intend to file early submissions with the FDA and other regulatory agencies. . “
The two companies’ vaccine, called Kommernati, has already been approved for use in children aged 12 and over in many countries, including the United States.
Children in the 5 to 11 age group received two doses equivalent to one-third of what was given to people 12 years of age and older.
The two companies are awaiting data on the effectiveness of the vaccine in children two to five years old and children six months to two years old, at the earliest in the last quarter of this year.
[ad_2]
Source link
